Enterprise Value
5.207B
Cash
2.354B
Avg Qtr Burn
-94.18M
Short % of Float
5.88%
Insider Ownership
0.74%
Institutional Own.
93.23%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
QALSODY™ (Tofersen) Details Amyotrophic lateral sclerosis | Approved Update | |
SPINRAZA Details Spinal muscular atrophy | Approved Quarterly sales | |
Eplontersen (AKCEA-TTR-LRx) Details Transthyretin amyloidosis | PDUFA Approval decision | |
ION363 Details ALS (Amyotrophic Lateral Sclerosis) | Phase 3 Data readout | |
Eplontersen (AKCEA-TTR-LRx) Details Transthyretin Amyloid Cardiomyopathy, Transthyretin amyloidosis | Phase 3 Data readout | |
IONIS-APOCIII-LRx (Olezarsen) Details Severe hypertriglyceridemia | Phase 3 Data readout | |
Donidalorsen (IONIS-PKK-LRx) Details Hereditary angioedema | Phase 3 Data readout | |
IONIS-APOCIII-LRx (Olezarsen) Details Familial chylomicronemia syndrome | Phase 3 Data readout | |
Bepirovirsen (IONIS-HBVRx) Details Hepatitis B | Phase 3 Update | |
Zilganersen (ION373) Details Alexander Disease | Phase 2/3 Data readout | |
ION224 Details Non-alcoholic steatohepatitis | Phase 2b Data readout | |
Fesomersen (IONIS-FXI-LRx) Details Hepatitis B | Phase 2b Update | |
IONIS-MAPTRx (BIIB080) Details Alzheimer's disease | Phase 2 Data readout | |
Tominersen (IONIS-HTT Rx) Details Huntington's disease | Phase 2 Update | |
IONIS-AGT-LRx Details Pulmonary hypertension, Heart failure | Phase 2 Update | |
Cimdelirsen (IONIS-GHR-LRx) Details Acromegaly | Failed Discontinued | |
IONIS-ENaC-2.5Rx (antisense medicine) Details Cystic fibrosis | Failed Discontinued |